Shares of Tandem Diabetes Care Inc. (NASDAQ:TNDM) were up 3.9% during mid-day trading on Monday . The stock traded as high as $7.01 and last traded at $6.91, with a volume of 119,852 shares trading hands. The stock had previously closed at $6.65.

Several analysts recently issued reports on TNDM shares. Zacks Investment Research downgraded Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. Robert W. Baird reaffirmed a “buy” rating on shares of Tandem Diabetes Care in a research note on Monday, May 2nd. Sterne Agee CRT reaffirmed a “neutral” rating on shares of Tandem Diabetes Care in a research note on Monday, May 16th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of Tandem Diabetes Care in a research note on Wednesday, June 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $14.21.

The stock’s 50-day moving average price is $7.21 and its 200-day moving average price is $7.98. The firm’s market capitalization is $211.23 million.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, July 28th. The medical device company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.05. The company earned $23 million during the quarter, compared to analyst estimates of $23.08 million. Tandem Diabetes Care’s revenue for the quarter was up 46.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.65) EPS. On average, equities analysts expect that Tandem Diabetes Care Inc. will post ($2.14) earnings per share for the current year.

In related news, EVP John F. Sheridan sold 15,000 shares of the stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $6.52, for a total value of $97,800.00. Following the completion of the sale, the executive vice president now owns 22,763 shares of the company’s stock, valued at $148,414.76. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.